论文部分内容阅读
目的:研究急性冠状动脉综合征(acutecoronarysyndrome,ACS)患者血清白介素-6和C反应蛋白水平的变化,为ACS的早期预防及临床干预治疗提供参考。方法:用酶联免疫吸附法测定30例ACS患者和18例稳定型心绞痛(stableanginapectoris,SAP)患者和26名正常人(对照组)的白介素-6、C反应蛋白水平,比较ACS组和SAP组入院时和住院3周后的白介素-6、C反应蛋白水平变化情况。结果:ACS组入院时和住院3周后白介素-6犤(254±70)ng/L,(239±67)ng/L犦、C反应蛋白水平犤(38±18)ng/L,(35±17)ng/L犦分别与SAP组犤(113±41)ng/L、(109±40)ng/L、(4.9±1.8)ng/L、(4.7±2.0)ng/L犦、对照组犤(93±39)ng/L、(3.7±1.5)ng/L犦比较差异均有统计学意义,均为P<0.01,ACS组入院时与住院治疗3周后的白介素-6、C反应蛋白水平比较差异均无统计学意义(均为P>0.05)。而SAP组入院时和住院3周后的白介素-6、C反应蛋白水平与对照组比较差异亦无统计学意义,均为P>0.05。结论:ACS患者血清白介素-6、C反应蛋白水平显著升高,提示炎症反应可能参与了ACS的发生、发展过程,白介素-6、C反应蛋白可作为监测病情的临床生化指标。
Objective: To study the changes of serum interleukin-6 and C-reactive protein levels in patients with acute coronary syndrome (ACS), and provide a reference for the early prevention and clinical intervention of ACS. Methods: The levels of interleukin-6 and C-reactive protein in 30 patients with ACS and 18 patients with stable angina pectoris (SAP) and 26 normal controls (control group) were measured by enzyme-linked immunosorbent assay Changes in interleukin-6 and C-reactive protein levels at admission and 3 weeks after hospitalization. Results: The levels of interleukin -6 犤 (254 ± 70) ng / L, (239 ± 67) ng / L 犦, C-reactive protein ACS 38 ± 18 ng / L, ± 17 ng / L, respectively, were significantly higher than those in SAP group (113 ± 41 ng / L, 109 ± 40 ng / L, 4.9 ± 1.8 ng / L and 4.7 ± 2.0 ng / The difference was statistically significant between the groups (93 ± 39) ng / L and (3.7 ± 1.5) ng / L,, both P <0.01. Interleukin-6, C There was no significant difference in the level of reactive protein (all P> 0.05). However, there were no significant differences in the levels of interleukin-6 and C-reactive protein between the SAP group and the control group at admission and 3 weeks after hospitalization, all of which were P> 0.05. Conclusions: Serum levels of interleukin-6 and C-reactive protein were significantly increased in patients with ACS, suggesting that inflammatory reaction may be involved in the occurrence and development of ACS. Interleukin-6 and C-reactive protein may be used as clinical and biochemical indicators to monitor the disease.